Period:
Draw Mode:
| Volume | 723,262 |
|
|||||
| News | - | ||||||
| Day High | 0.1899 | Low High |
|||||
| Day Low | 0.175 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.01042 | 5.95% | 0.18542 | 15:59:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.175 | 0.175 | 0.1899 | 0.18542 | 0.175 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 146 | 723,262 | $ 0.182512 | $ 132,004 | - | 0.15 - 0.52 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | formt | 100 | $ 0.1788 | USD |
CytoDyn Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 169.2M | 921.12M | 556.02M | 0 | -79.82M | -0.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.184 | 0.1925 | 0.1701 | 0.1796223 | 1,202,406 | 0.00142 | 0.77% |
| 1 Month | 0.21 | 0.2428 | 0.1701 | 0.1930703 | 863,178 | -0.02458 | -11.7% |
| 3 Months | 0.27 | 0.285 | 0.1701 | 0.2119058 | 1,567,695 | -0.08458 | -31.33% |
| 6 Months | 0.37 | 0.395 | 0.1701 | 0.2474731 | 1,375,042 | -0.18458 | -49.89% |
| 1 Year | 0.45 | 0.52 | 0.15 | 0.2835455 | 1,618,185 | -0.26458 | -58.8% |
| 3 Years | 3.21 | 7.70 | 0.15 | 1.86 | 2,583,253 | -3.02 | -94.22% |
| 5 Years | 0.525 | 10.01 | 0.0552 | 2.35 | 2,637,848 | -0.33958 | -64.68% |
CytoDyn (QB) Description
| CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. |